Amgen finally gets approval for Prolia – After months of delay, Amgen finally won FDA approval for Prolia, an injectable treatment for postmenopausal women with osteoporosis who are at high risk for fractures. The endorsement is a big boost for the biotech, which has been counting on Prolia to reverse a series of setbacks over the past few years, notably a decline in sales of some of its largest-selling products, Aranesp and Enbrel…more
Encouraging early-early-early result? Sure. Overly optimistic headline? Of course. New vaccine “could eliminate breast cancer.” Sally Church gives us some good cautionary words about over-hyping such results.
Biogen sues multiple rivals over MS drug – seeks royalties. I’m sure the lawyers, at least, are happy about this development.
Territory Management Training. We’ve got the vendor/partners you need for this – contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
Sales and Account Manager, Training Agency serving Life Sciences (Massachusetts), experience required. From the Impactiviti Job Board.
Looking Forward to the SPBT Conference – here’s what I’ll be doing, and the workshops that look appealing. Will I see you there? Download my digital business card (see linked post) and let’s get together in Orlando! (SPBT = Society of Pharmaceutical and Biotech Trainers)
JUST FOR FUN
16 Thin Buildings. Actually, I’d prefer to see one thinner consultant, in the mirror. Sigh.
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Visit the Impactiviti Job Board